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Cancer risk is highly variable in carriers of the common TP53-R337H founder allele, possibly due to the influence 
of modifier genes. Whole-genome sequencing identified a variant in the tumor suppressor XAF1 (E134*/Glu134Ter/
rs146752602) in a subset of R337H carriers. Haplotype-defining variants were verified in 203 patients with cancer, 
582 relatives, and 42,438 newborns. The compound mutant haplotype was enriched in patients with cancer, con-
ferring risk for sarcoma (P = 0.003) and subsequent malignancies (P = 0.006). Functional analyses demonstrated 
that wild-type XAF1 enhances transactivation of wild-type and hypomorphic TP53 variants, whereas XAF1-E134* 
is markedly attenuated in this activity. We propose that cosegregation of XAF1-E134* and TP53-R337H mutations 
leads to a more aggressive cancer phenotype than TP53-R337H alone, with implications for genetic counseling 
and clinical management of hypomorphic TP53 mutant carriers.
INTRODUCTION
The cancer phenotype conferred by germline TP53 mutations is 
characterized by marked clinical heterogeneity, with no obvious 
pattern in age of onset, cancer type, and likelihood of subsequent 
malignancies (1). Carriers of pathogenic TP53 variants are susceptible 
to a wide spectrum of childhood and adult-onset malignancies, and 
phenotypic variability exists among carriers, suggesting that environ-
mental and additional genetic factors contribute to cancer risk. Epi-
demiological and clinical studies revealed the presence of a unique 
TP53-R337H mutation in Southern and Southeastern Brazil (2–4). 
Carriers of the founder R337H allele have an increased risk of devel-
oping adrenocortical tumors (ACTs) (2–4) and other tumor types, 
such as breast carcinoma, soft-tissue sarcoma, osteosarcoma, choroid 
plexus carcinoma (CPC), and thyroid and lung cancers (5–11). Fur-
thermore, family histories of cancer associated with the founder 
TP53-R337H allele range from isolated cancer cases to those fulfilling 
classic criteria for Li-Fraumeni syndrome (12).
Although R337H is the only reported widespread TP53 founder 
allele (4), the extended constitutive haplotype shared by carriers has 
not been established. We propose that additional variants and poly-
morphisms in the TP53-R337H haplotype contribute to phenotypic 
variation and cancer risk. Whole-genome sequencing (WGS) and 
whole-exome sequencing (WES) analyses of pediatric ACTs asso-
ciated with the TP53-R337H allele (13) identified a subset of cases 
who share a recurrent long-range chromosome 17p13 haplotype, 
containing a nonsense variant (E134*) in the X-linked inhibitor of 
apoptosis (XIAP)–associated factor 1 (XAF1) gene a putative tumor 
suppressor functioning in a positive feedback loop with p53 (14). 
Given the heterogeneity of cancer phenotypes among TP53-R337H 
carriers and the existence of divergent haplotypes, one of them seg-
regating both mutated alleles, we determined whether XAF1 acts as 
a modifier of p53 function and cancer susceptibility.
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RESULTS
Delineating the common haplotype shared by  
TP53-R337H carriers
WGS and WES analyses of 12 unrelated Brazilian patients with ACT 
carrying the TP53-R337H allele (13) revealed an identical 29,971–base 
pair (bp) sequence (chr17: 7,570,956 to 7,600,926, GRCh37/hg19; 
corresponding to 0.046 cM based on HapMap) in all carriers. This 
region encompasses the TP53 and WRAP53 loci and the correspond-
ing internal polymorphisms (hereafter referred to as R337H-only 
haplotype; Fig. 1). Of note, the TP53-R337H founder allele (4) bears 
one copy (nonduplicate) of the 16-bp polymorphism in intron 3 
(rs17878362) and arginine at codon 72 (rs1042522). Furthermore, a 
long-range haplotype encompassing a 1,868,598-bp region (chr17: 
6,140,570 to 8,009,167, GRCh37/hg19; corresponding to 4.44 cM 
based on HapMap) was identified in a subset of ACT cases (5 of 12; 
42%) (hereafter referred to as extended haplotype). This extended 
haplotype harbors the “T” allele for single-nucleotide polymorphism 
(SNP) rs146752602 (chr17: 6,663,899, GRCh37/hg19), resulting in 
a stop-gain variant (E134*/Glu134Ter) in the putative tumor suppressor 
XAF1 (Fig. 1). Rare variants observed in the 2-Mb region of chromosome 
17p13 were annotated. Only the XAF1-E134* variant showed consistent 
segregation with the TP53-R337H allele within this region (table S1).
The R337H haplotypes were further verified by phasing, using 
genome-wide SNP array data from five unrelated multigenerational 
TP53-R337H families. Although array data lacked sufficient density 
to capture the full complement of SNPs obtained by WGS/WES, 
we inferred genotypes and concluded that TP53-R337H carriers 
in these families share the common extended haplotype (Fig. 2A) 
that cosegregates with affected family members. The extended 
haplotype containing TP53-R337H and XAF1-E134* alleles was 
also present in relatives not expressing a cancer phenotype, indicating 
that the combined mutations may not confer complete penetrance 
(Fig. 2, B and C) (15).
The estimated age of the extended haplotype is 577 years [assum-
ing a 28-year generation time; 95% confidence interval (CI), 208 to 
1853] (16), bracketing with colonization of Brazil by Europeans and 
its previously suggested dispersal route into Southern Brazil (17). 
Consistently, all four R337H carriers from Europe (Spain, Portugal, 
and France) included in our study share the common TP53-R337H 
founder allele as the Brazilians. However, the extended haplotype was 
observed in the Spanish families and a subset of Brazilian carriers.
TP53-R337H and XAF1-E134* allele frequencies
The TP53-R337H variant (rs121912664) is rare and virtually absent 
in a worldwide meta-cohort, with an allele frequency of 0.000009151 
(gnomAD V2.1.1 control dataset) (18). The TP53-R337H allele 
was not identified in cancer-free participants reported in the 
ABraOM (Arquivo Brasileiro Online de Mutações (19) and SELA 
Fig. 1. Schematic diagram of chromosome 17p13 spanning 2-Mb region encompassing TP53-R337H and XAF1-E134* variants. Identification and location of genes 
in this region as well as the genotyped SNPs and microsatellite markers are shown. Positions are given relative to build GRCh37/hg19. R337H-only and extended (TP53-
R337H + XAF1-E134*) haplotypes observed in the population cohort study are represented.
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(Serviço de Sequenciamento em Larga Escala) exome sequence data-
bases (1348 Southeastern Brazilian individuals and 2696 chromosomes) 
and Global Biobank Engine dataset (337,199 British individuals) (20). 
However, a neonatal screening study of 171,649 newborns in Paraná, 
Southern Brazil detected this variant in 461 individuals (three 
homozygous carriers), corresponding to an estimated allele frequen-
cy of 0.001 (21). The TP53-R337H variant is reported in ClinVar 
(22) as pathogenic (allele ID: 12379).
The XAF1-E134* allele (rs146752602) is observed in non-Finnish 
Europeans (762 of 128,578 alleles) and worldwide (978 of 281,940 
alleles) at an allele frequency of 0.006 and 0.004, respectively (https://
gnomad.broadinstitute.org/variant/17-6663899-G-T) (18). This 
variant occurred at an allele frequency of 0.007 in the Global Bio-
bank Engine database (20) and 0.004 in the ABraOM (19) and SELA 
Brazilian databases.
The XAF1-E134* variant was also identified in 38 adult survivors 
of childhood cancer (allelic frequency of 0.006) in the St. Jude Life-
time (SJLIFE) cohort (23). Notably, one patient who had developed 
rhabdomyosarcoma also harbored the hypomorphic TP53-G187S 
variant. Two additional potentially pathogenic germline XAF1 
mutations were observed in neuroblastoma (XAF1-K235fs) and 
Hodgkin’s lymphoma (XAF1-Q283*) survivors, both with germline 
wild-type TP53 (wt-TP53).
TP53-R337H and XAF1-E134* frequencies in newborns 
from Southern Brazil
In a general screening of 42,438 newborns from Southern Brazil, we 
identified 147 TP53-R337H carriers. Notably, 101 (69%) also harbored 
the XAF1-E134* variant. Analysis of parental genomic DNA revealed 
that both mutated alleles segregated from the same parent. Family 
history of cancer was unknown for all positive cases.
The frequency of the single XAF1-E134* allele in Southern Brazil 
was verified by genotyping 3000 newborns negative for the TP53-
R337H variant. We identified 23 XAF1-E134*–positive individuals, 
corresponding to an allele frequency of 0.004 (23 of 6000 chromo-
somes), consistent with the ABraOM (19) and SELA databases.
R337H-only and extended haplotype frequency in  
cancer populations
Genotyping of 203 patients with cancer carrying the TP53-R337H 
founder allele demonstrated that 161 also harbored the XAF1-E134* 
variant. Segregation analysis determined that both mutated alleles 
were within the same haplotype. Four homozygous R337H and 
E134* carriers (proband nos. 46, 61, 90, and 193; table S2) were excluded 
from further cancer risk analysis to mitigate potentially confounding 
effects. The relative frequency of the extended haplotype in the remaining 
199 patients with cancer was higher (79%) [odds ratio (OR), 1.70; 95% CI, 
Fig. 2. Risk haplotype and representative pedigrees associated with the extended haplotype as determined by phasing. (A) Common SNPs from the Axiom array 
spanning 2-Mb region in the chromosome 17p13 (see Fig. 1). Of the rare variants falling within haplotype boundaries, only TP53-R337H and XAF1-E134* variants remained 
after filtering for pathogenicity. ExAC: Exome Aggregation Consortium; MAF: Minor Allele Frequency. (B) Brazilian family (proband no. 108; table S2) diagnosed with 
angiosarcoma and their relatives. SNPs were used to phase the haplotypes. The risk haplotype harboring both mutant alleles (TP53-R337H and XAF1-E134*) is represented 
in red bars. The remaining haplotype is represented by different colors as segregating in family members. (C) Spanish family (proband no. 50; table S2). Age at diagnosis 
and present age or age at death are indicated in each pedigree. ExAC, Exome Aggregation Consortium; MAF, Minor Allele Frequency.
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1.10 to Inf (Infinity); P = 0.022] (Table 1) compared to the newborn group. 
Stratifying by tumor type, the extended haplotype (93%) was also 
enriched in patients with a first diagnosis of sarcoma (OR, 6.33; 95% CI, 
1.76 to Inf; P = 0.003) (Table 1). Ten additional patients diagnosed with 
CPC (n = 3), prostate (n = 2), lymphoma (n = 2), thyroid (n = 1), 
lung (n = 1), and renal (n = 1) carcinoma (Table 1 and table S2) were 
collectively analyzed as a group because of limited sample size. All 
harbored the extended haplotype cosegregating the TP53-R337H and 
XAF1-E134* alleles (Table 1). The relative frequency of the extended 
haplotype in patients with ACT and breast cancer was comparable to 
the newborn group even when considering age at diagnosis (Table 1).
Multiple primary tumors across TP53-R337H carriers
Thirty-three probands (29 females and 4 males) developed multiple 
primary malignancies (Table 1 and table S2), 30 of which harbored 
the extended haplotype spanning both mutated alleles (91%) (OR, 
4.53; 95% CI, 1.52 to Inf; P = 0.006) (Fig. 3). Patients with breast 
cancer constitute 52% of these cases (17 of 33), with 16 (including 
all contralateral breast cancers) harboring the extended haplotype 
(table S2). Notably, patients developing a third (n = 12) or fourth 
(n = 3) primary tumor were exclusively associated with the extended 
haplotype (Fig. 3 and table S2).
Considering all tumor types after first diagnosis (n = 48), 
sarcomas were most prevalent (n = 14; 29%) and included three cases of 
malignant phyllodes of the breast, followed by breast cancer (n = 11; 23%) 
and adrenocortical carcinoma (n = 4; 8%) (Fig. 3 and table S2).
Family cancer history
Inspection of the 203 pedigrees identified six families that fulfilled 
classic LFS (Li-Fraumeni syndrome) criteria, whereas the majority met 
the revised Chompret criteria (n = 141; table S2) (1). Most probands 
shared the R337H-only or extended haplotype with one parent. 
However, recombination events leading to the loss of XAF1-E134* 
(n = 3) or TP53-R337H (n = 1) alleles were observed in individuals 
from four independent families (nos. 79, 92, 131, and 149) (table S2). 
For instance, proband no. 149 diagnosed with breast cancer at 
age 27 was positive for the TP53-R337H founder allele but negative 
for the XAF1-E134* variant, whereas her sister who developed 
breast cancer at age 29 shared both derived alleles with their mother. 
Their father tested negative for both variants.
Exogenous XAF1 increases p53 transcriptional activity
To study the effect of XAF1 on p53 transactivation function, we 
transiently transfected Saos-2 cells with promoter-luciferase reporters 
with or without p53 and XAF1 expression vectors. wt-TP53 strongly 
induced the promoter containing intact p53-binding consensus sites 
(PG13) but not mutant sites (MG15). Full-length wild-type XAF1 
(wt-XAF1) and XAF1-E134* had no effect individually or combined 
with either reporter (Fig. 4A and fig. S1A). However, wt-XAF1 stim-
ulated wt-p53 transactivation, leading to increased luciferase expres-
sion. The nonsense XAF1-E134* was remarkably attenuated in 
activating p53 and interfered with wt-XAF1 by blocking its ability to 
increase p53 transactivation in a dominant-negative manner (Fig. 4A 
and fig. S1A). Comparable transactivation results were obtained using 
TP53-R337H (Fig. 4A and fig. S1A). Western blot analysis showed 
that changes in promoter-reporter activities in response to p53 due 
to coexpression with wt-XAF1 and/or XAF1-E134* were not a result 
of altered protein levels (Fig. 4B and fig. S1B). Studies with an inde-
pendent p53-responsive promoter-reporter (p50-2) yielded essentially 
identical results (fig. S1, C and D). Of interest, wt-XAF1, but not 
Table 1. Tumor distribution in probands harboring R337H-only and extended haplotype.  




FDR P OR* CI
Control (newborn 
screening) 147 46 101 — — — —
ACT [total cases (N)] 102 26 76 0.314 0.198 1.33 0.799 to Inf
ACT (<5 years) 77 20 57 0.314 0.251 1.297 0.742 to Inf
ACT (≥5 years) 25 6 19 0.351 0.316 1.439 0.586 to Inf
Sarcomas 30 2 28 0.03 0.003 6.329 1.756 to Inf
Breast cancer [total 
cases (N)] 57 14 43 0.314 0.22 1.397 0.743 to Inf
Breast cancer (≤45 
years) 31 7 24 0.314 0.23 1.558 0.680 to Inf
Breast cancer (>45 
years) 26 7 19 0.423 0.423 1.235 0.524 to Inf
Other cancers 10 0 10 0.07 0.028 9.621 1.245 to Inf
Total 199† 42 157 0.07 0.022 1.7 1.097 to Inf
Multiple tumors 
[total cases (N)] 33 3 30 0.03 0.006 4.525 1.517 to Inf
 *For other cancers, group OR was estimated by adding 0.5 to the contingency table. Other ORs are conditional maximum likelihood estimator.   †Four 
probands (three ACTs and one CPC) homozygous for both variants were excluded from the analysis so all individuals in the analysis are heterozygous for 
TP53-R337H.







Pinto et al., Sci. Adv. 2020; 6 : eaba3231     24 June 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
5 of 10
XAF1-E134*, stimulated the transactivation function of other hypo-
morphic p53 variants such as T125M, R175L, R290H, and G334R 
(Fig. 4). The pathogenic DNA binding mutant TP53-R175H was 
transcriptionally inactive irrespective of XAF1. These findings 
support XAF1 as a functional modifier of wild-type, R337H, and 
other hypomorphic p53 variants.
Endogenous XAF1 modifies p53 function in primary human 
fibroblasts
To study the modifier effect of XAF1 upon p53 under more physio-
logical conditions, we analyzed three low-passage primary human 
fibroblast lines derived from individuals with the following 
genotypes: (i) wt-XAF1 and wt-TP53 (HF001), (ii) heterozygous 
XAF1-E134* and TP53-R337H haplotype (HF003), and (iii) homo-
zygous XAF1-E134* and TP53-R337H (HF004). As expected, un-
treated HF001 cells expressed a basal level of endogenous wild-type 
p53, which was markedly induced in parallel with its target genes 
p21CIP1, PUMA, and MDM2 in response to ionizing radiation (IR) 
[5 grays (Gy)] (Fig. 5A). Similarly, p21CIP1, PUMA, and MDM2 
were induced upon DNA damage in the heterozygous HF003 fibro-
blasts. By contrast, p21CIP1, PUMA, and MDM2 basal levels are 
low in untreated HF004 fibroblasts and remain unaltered following 
DNA damage, despite expressing high levels of p53-R337H. These 
findings suggest that the p53 pathway is functionally compromised 
in these cells (Fig. 5A). The primary fibroblasts may be defective in 
the IR response due to the loss of functional XAF1. To address this 
hypothesis, we used a CRISPR-Cas9 approach to correct the endog-
enous XAF1-E134* allele and restore wt-XAF1 expression in these 
cells. Two successfully edited independent clones were identified 
(HF004-cl1 and HF004-cl2), each harboring wild-type and mutant 
XAF1 alleles. Re-establishing wt-XAF1 resulted in high expression 
of full-length XAF1, possibly due to copy-number gain of chromo-
some 17  in a subset of cells (fig. S2), and restoration of p21CIP1 
basal expression in HF004-cl1 and HF004-cl2 cells (Fig. 5A). DNA 
damage moderately induced p21CIP1, PUMA, and MDM2 (Fig. 5A). 
These findings support a physiologic role for endogenous XAF1 
as a positive regulator of p53 function.
Gene set enrichment analysis (GSEA) was performed to compare 
transcriptional programs active in parental HF004 and derived 
edited clones (HF004-cl1 and HF004-cl2) cell lines before and after 
IR. Consistently, p53 was among the top significant pathways iden-
tified (Fig. 5B and tables S3 and S4). p53 activity was compromised 
in parental cells but restored in both clones (Fig. 5B). In addition, 
apoptosis and G2-M checkpoint pathways were also identified as the 
principal involved pathways in this analysis (fig. S3 and tables S3 
and S4). Our results provide previously unidentified insights into 
cancer cell signaling by including XAF1 as modulator of p53 activity.
DISCUSSION
WGS and WES analyses of pediatric ACTs from Southern Brazil 
identified a common locus containing identical TP53 and WRAP53 
Fig. 3. Distribution of tumor types as a second, third, or fourth malignancy among patients with the R337H-only and extended haplotypes. Thirty-three probands 
(29 females and 4 males) developed multiple primary malignancies. Multiple primary tumors in probands with the extended haplotype (n = 30) are visualized in the upper 
panel. Multiple primary tumors in probands with the R337H-only haplotype (n = 3) are visualized in the lower panel.
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sequences, including corresponding polymorphisms in all TP53-
R337H carriers. Moreover, an extended chromosome 17p13 haplotype 
containing a nonsense mutation in the putative tumor-suppressor 
gene XAF1 (E134*) was observed in a subset of cases. These divergent 
haplotypes were verified in newborns from Southern Brazil, showing that 
69% of TP53-R337H haplotypes also harbor the XAF1-E134* variant.
XAF1 is a zinc-finger, pro-apoptotic protein that was originally 
identified in a yeast two-hybrid screen using XIAP as the bait (24). 
Expression of XAF1 is frequently inactivated in human cancers, pri-
marily due to aberrant promoter methylation and gene silencing, 
implicating XAF1 in tumor suppression (25). Gain- and loss-of-
function studies using cell lines and mouse xenograft models further 
support XAF1 as a tumor suppressor (14, 25–29). Ectopic expression 
of XAF1 in parental HCT116 (TP53+/+) cells markedly repressed 
xenograft tumor growth. In contrast, genetically engineered HCT116 
cells that lack endogenous TP53 (TP53−/−) were resistant to XAF1 
overexpression and continued to grow in vivo (14). XAF1 reportedly 
functions in a positive feedback loop with p53, in part, by binding 
directly to the N-terminal proline-rich domain of p53, thereby inter-
fering with MDM2 binding and ubiquitination of p53 (14). Together, 
these findings demonstrate that XAF1 can function as a tumor sup-
pressor in a p53-dependent manner.
Consistent with these findings, our promoter-reporter studies 
demonstrate that full-length exogenous XAF1 enhances the trans-
activation function of wild-type, R337H, and other hypomorphic 
p53 variants, whereas XAF1-E134* is markedly attenuated in this 
regulatory activity. In addition, correction of endogenous of mutant 
XAF1 in low-passage human HF004 fibroblasts (XAF1E134*/E134*; 
TP53R337H/R337H) by CRISPR-Cas9 gene editing restored full-length 
XAF1 expression, reestablished the p21CIP1 basal expression, and 
the induction of p21CIP1, PUMA, and MDM2 levels upon DNA 
damage. Furthermore, GSEA identified p53, apoptosis, and G2-M 
Fig. 4. XAF1 increases the transcriptional activity of hypomorphic TP53 variants. Saos-2 cells were transiently transfected with p53-responsive promoter-luciferase 
reporters with or without p53 and XAF1 expression vectors, as described in the Supplementary Materials. PG13 promoter-reporter luciferase assay. Wild-type XAF1, but 
not XAF1-E134*, stimulated the transactivation function of wild-type p53 and other hypomorphic p53 variants such as T125M, R175L, R290H, and G334R. (A) Western blot analysis 
of p53 and XAF1 in the transfected cell lysates. (B) The columns represent the mean of three independent experiments (±SD), each performed in duplicate. Error bars indicate 
SDs. Asterisks indicate statistical significance, as determined by one-way analysis of variance (ANOVA) *P < 0.005; **P = 0.0096; ***P = 0.0009; ****P = <0.0001.
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checkpoint pathways among the highest ranked in the XAF1 reversed 
engineered cell clones (HF004-cl1 and HF004-cl2) compared to the 
HF004 parental cells. These data support XAF1 as a physiological 
modulator of p53 function.
Given that XAF1 can modify p53 function, it is reasonable to 
propose that the extended haplotype could affect tumor type, age of 
onset, and/or penetrance in TP53-R337H carriers. Genetic screen-
ing of 42,438 Southern Brazilian newborns revealed that 1 in 290 
individuals harbored the TP53-R337H mutation, 69% of which was 
also positive for the XAF1-E134* mutation. We understand that 
positive carriers in this group are cancer prone but with unknown 
risk, which may reduce the power of detecting an association be-
tween haplotype and cancer susceptibility. Nevertheless, the extended 
haplotype harboring both mutated alleles was significantly enriched 
in patients who developed sarcoma at first diagnosis (93%) com-
pared to the newborn group (69%). In addition, sarcoma was the 
most prevalent cancer in subsequent primary tumor diagnoses and 
one of the most frequently reported malignancies in family mem-
bers of probands with the extended haplotype. These findings raise 
the intriguing possibility that XAF1 and p53 may have tissue-specific 
functions, consistent with other inherited mutations predisposing 
carriers to specific tumor types, such as BRCA1/BRCA2, RB, or WT1 
(30, 31). The impact of XAF1-E134* on TP53-R337H is further evi-
dent by the significant excess of multiple primary cancers in carriers 
of the extended haplotype (91%).
Recombination events were observed whereby individuals from 
families associated with the extended haplotype have lost either the 
TP53-R337H or XAF1-E134* allele. These findings underscore the 
need to validate not only TP53 status but also the constitutive chro-
mosome 17p13 haplotype in the proband and extended family 
members. The clinical significance and impact of the R337H variant 
and the corresponding haplotype will be particularly important for 
future studies assessing penetrance and cancer risk.
In conclusion, we identified XAF1-E134* as a linked variant that 
acts in concert with the TP53-R337H allele in modulating the cancer 
phenotype. These findings suggest that the R337H haplotype may 
Fig. 5. Correction of the XAF1-E134* mutation using CRISPR-Cas9 in human low-passage fibroblasts restores full-length XAF1 and partial p53 responsiveness. 
(A) Western blot analysis of MDM2, XAF1, p21CIP1, PUMA, and p53 expression in untreated and irradiated (5 Gy) low-passage fibroblasts. HF001 (wild-type XAF1 and TP53), 
HF003 (heterozygous XAF1- E134*; TP53-R337H), HF004 (homozygous XAF1-E134*; TP53-R337H), and derived HF004 clones with CRISPR-Cas9–corrected E134*(HF004cl1 and 
HF004cl2). (B) Gene set enrichment analysis (GSEA) showing the enrichment of p53 pathway signature in edited clones and heat map showing the expression levels in 
each cell line before and after IR treatment. Color scale represents SDs from the mean (z-score; range, −2 to 2). FDR, false discovery rate.
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affect cancer risk more than simply the R337H allele alone. We also 
propose that the modifier function of XAF1 is relevant not only to 
the TP53-R337H founder allele but also to other hypomorphic TP53 
alleles. Further studies to advance our understanding of the impact 
of germline TP53 variants in the context of risk-modifying variants 
such as XAF1 will have important implications for genetic counseling, 
surveillance, and clinical management of carriers.
CONCLUSION
The heterogeneity of cancer phenotypes among carriers of the 
founder TP53-R337H mutation could be explained by the existence 
of divergent haplotypes, one of them cosegregating mutated alleles 
in two distinct tumor-suppressor genes: TP53 and XAF1. Screening 




Physicians from different institutions in Brazil and Europe provided 
DNA samples from patients with cancer, ascertained as a proband 
harboring the TP53-R337H allele. Cases were retrospectively selected 
on the basis of availability of genomic DNA and independent of age 
at diagnosis, cancer predisposition syndrome, or family history of 
cancer. Genotyping was performed on genomic DNA from 203 pa-
tients with cancer from Brazil (n = 199), Spain (n = 2), Portugal 
(n = 1), and France (n = 1) (fig. S4). Genomic DNA from 582 family 
members was also included. Haplotypes were determined by segre-
gation analysis of genomic DNA from parents and descendants or 
by loss of heterozygosity (LOH) in tumor samples or inferred by a 
population approach (Supplementary Materials). Clinical, demo-
graphic characteristics, and family history of cancer were available 
(Table 1 and table S2). Genomic DNA from 42,438 newborns 
undergoing routine genetic screening (Paraná State, Brazil, from 
January 2016 to July 2017) was analyzed using a polymerase chain 
reaction (PCR)–based assay (Supplementary Materials) to determine 
the frequencies of XAF1-E134* and TP53-R337H variants (newborn 
cohort). This study was approved by the local ethics committees and 
the institutional review board at St. Jude Children’s Research Hospital.
Haplotype reconstruction
A 2-Mb region on chromosome 17p13, including the TP53 locus 
(chr17: 6,000,000 to 8,000,000, GRCh37/hg19), was analyzed using 
WGS (n = 10) and WES (n = 2) data from 12 unrelated Brazilian 
patients with ACT harboring TP53-R337H allele (European Genome- 
phenome Archive: EGAS00001000257) (13). Because of chromosome 
17 copy-neutral LOH in tumor tissue (13), haplotypes of the 2-Mb 
region could be inferred without prior phasing. The resulting 
haplotypes were verified in 25 individuals (21 TP53-R337H carriers) 
from five unrelated families, with available SNP data obtained by 
Axiom Genome-Wide CEU 1 Array (Affymetrix) analysis (Supple-
mentary Materials).
Database query
TP53-R337H (rs121912664) and XAF1-E134* (rs146752602) variant 
frequencies were retrieved from the (i) Genome Aggregation Database 
(https://gnomad.broadinstitute.org/) (18); (ii) Global Biobank Engine 
with genome-wide association analysis of 337,199 white British in-
dividuals (20); and (iii) ABraOM (n = 609) (19) and SELA (n = 739) 
(www.premium.fm.usp.br/index.php?mpg=11.42.00&lab=SELA) 
databases, containing exome sequences of cancer-free individuals 
from Southeastern Brazil. TP53-R337H and XAF1-E134* variant 
frequencies were also derived from the SJLIFE cohort (23), with ge-
nomic information from 3006 adult survivors of childhood cancer.
Genetic, molecular, in vitro, and in vivo functional studies
TP53 and XAF1 variants were genotyped by PCR-restriction fragment- 
length polymorphism analysis and Sanger sequencing (fig. S5). The 
TP53 and XAF1 loci were mapped by SNPs and microsatellite marker 
analyses, as described in the Supplementary Materials. Functional 
promoter-reporter analyses and gene editing studies using CRISPR- 
Cas9 (correction of endogenous XAF1-E134* in primary human 
fibroblasts) and expression analysis by microarray and cytogenetic 
analysis are described in the Supplementary Materials.
Statistical analyses
Conditional on individuals harboring the germline TP53-R337H 
founder variant and a cancer diagnosis, a target cohort of 203 pa-
tients was analyzed. Within each tumor type observed, as total or 
stratified by age, we estimated the prevalence of the haplotype that 
segregates TP53-R337H and XAF1-E134* mutations, along with exact 
95% CI. A lower bound of the 95% CI not including the prevalence 
rate of 70% (observed in the newborn cohort) would be suggestive 
of an increased prevalence of this haplotype within that tumor type. 
Statistical analysis was carried out using GraphPad Prism and Stata 
v.12 packages.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/26/eaba3231/DC1
View/request a protocol for this paper from Bio-protocol.
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